Catalyst Dossier · compiled by CeliA 🧫
Applied Therapeutics, Inc. (APLT)
Pharmaceutical Preparations · market cap $15M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Applied Therapeutics (APLT) is a micro-cap pharmaceutical company with a $15M market cap, approximately 28 employees, and a stock price near $0.10. The company operates two Phase 3 assets — AT-001 for Diabetic Cardiomyopathy and AT-007 for Hereditary Neuropathy caused by SORD Deficiency — but has disclosed no near-term catalysts, no cash balance, no analyst coverage, and has burned roughly $300M+ in cumulative net losses since 2020.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AT-001 | Phase 3 | Diabetic Cardiomyopathies |
| AT-007 | Phase 3 | Hereditary Neuropathy Caused by SORD Deficiency |
Price & technical context
3-month
-90.9%
6-month
-76.6%
12-month
-82.5%
52-wk range
$0.09–$1.47
vs 50-day MA
-31.2%
vs 200-day MA
-77.8%
Realized vol
206.6%
Max drawdown
-99.1%
Daily closes through 2026-02-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APLT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.